Indication
HER2-Positive Solid Tumors
1 clinical trial
1 product
Clinical trial
A Phase I, Open-label, Dose Escalation Clinical Trial to Assess the Safety, Efficacy, Tolerability and Pharmacokinetics of the Recombinant Humanized Anti-PD1 Monoclonal Antiody (JS001) in Combination With Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate (RC48-ADC) in Treatment of HER2-Positive Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
RC48-ADC